Patricia Carr - Mar 3, 2023 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
SVP, Chief Accounting Officer
Signature
By: /s/Adam Guttmann, as attorney in fact For: Patricia Carr
Stock symbol
JAZZ
Transactions as of
Mar 3, 2023
Transactions value $
-$161,594
Form type
4
Date filed
3/7/2023, 08:18 PM
Previous filing
Dec 7, 2022
Next filing
Mar 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Award $0 +2.52K +42.52% $0.00 8.46K Mar 3, 2023 Direct F1
transaction JAZZ Ordinary Shares Sale -$162K -1.15K -13.57% $140.76 7.31K Mar 5, 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
F2 Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F3 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7559 to $140.7631. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.